3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
27
Unknown
13
Recruiting
8
Terminated
6
Active not recruiting
4
Not yet recruiting
3
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
20
Rectal Neoplasms
12
Colonic Neoplasms
11
Head and Neck Neoplasms
6
Neoplasm Metastasis
5
Carcinoma, Hepatocellular
5
Squamous Cell Carcinoma of Head and Neck
4
Pancreatic Neoplasms
4
Neoplasms
3
Keratosis, Actinic
3
Esophageal Neoplasms
3
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Skin Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Nasopharyngeal Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Squamous Cell
2
Carcinoma, Non-Small-Cell Lung
2
Biliary Tract Neoplasms
2
Adenocarcinoma Of Esophagus
2
Tongue Neoplasms
1
Recurrence
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Mouth Neoplasms
1
Motor Activity
1
Melanoma
1
Malignant Tumor of Pancreas Metastatic to Liver
1
Lymphoma, Non-Hodgkin
1
Interventions
nimotuzumab
4
Paclitaxel
3
Surgical Procedures, Operative
2
Cisplatin
2
sintilimab
1
pembrolizumab
1
monalizumab
1
epacadostat
1
Taxes
1
TP protocol
1
Saline Solution
1
Radiation
1
Oxaliplatin
1
Nimodipine
1
Metabolic Networks and Pathways
1
Fluorouracil
1
Biopsy
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Esophageal Squamous Cell Carcinoma
×
Fluorouracil
×
Clear all
NCT03307941
2017-12-19
ARTEMIS-Eso
Jules Bordet Institute
Phase 1/2
Withdrawn